Hypoxia Silences STING, Weakens Cancer Immunity

This study explored how low oxygen levels, or hypoxia, in tumors affect a crucial immune pathway involving the stimulator of interferon genes (STING). STING is vital for detecting harmful DNA in cells and triggering immune responses against tumors. The researchers aimed to understand why STING is often less active in cancer and how this affects cancer progression.

Understanding the mechanisms that silence STING in tumors is important because STING helps the immune system fight cancer. If hypoxia silences STING, it might make tumors more resistant to treatments and lead to poorer outcomes for patients. This research could lead to new strategies to boost STING activity, improving cancer therapies.

The researchers studied various cancer cell lines and used mice with implanted tumors to observe the effects of hypoxia on STING. They focused on changes in gene expression and the role of specific proteins that modify DNA structure, such as lysine demethylases (KDM1A and KDM5A). They also examined how these changes affected the response to STING-activating treatments.

The study found that hypoxia reduced STING expression in several cancer types by altering DNA and protein structures in a process dependent on a protein called HIF-1α. This silencing made tumors less responsive to STING agonists, which are substances that activate STING. Inhibiting the protein KDM1A reversed this silencing, suggesting it as a potential target to restore STING activity.

The findings suggest that targeting KDM1A could restore STING function in tumors, potentially enhancing the effectiveness of cancer therapies. By understanding the role of hypoxia in suppressing immune responses, researchers can develop strategies to counteract this effect, improving patient outcomes.

Future research should focus on further understanding the interplay between hypoxia, STING silencing, and the role of metabolic changes in tumors. Testing KDM1A inhibitors in combination with existing cancer therapies could also provide insights into new treatment approaches.

This research was supported by the National Institutes of Health (awards R01ES005775 and R35CA197574). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Yale University also provided funding and support for this research.